Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jul 29;17(3-4):56–71. doi: 10.1080/15476278.2021.1954769

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 Taylor & Francis Group, LLC

PMC Copyright notice

Figure 1. — Short 1,25-(OH)₂VitD₃ pre-treatment effects on osteogenic and angiogenic gene expression of hASCs seeded on PLGA/β-TCP/PCL scaffold after 2 weeks. 30 min 1,25-(OH)₂VitD₃ pre-treatment increased (a) Ki-67 by 10.8-fold, (b) ALP by 43.2-fold, (c) OPN by 2.4-fold, (d) SPARC by 2.6-fold, decreased (e) VEGF₁₈₉ by 0.78-fold, and enhanced (f) VDR by 4.9-fold compared to non-treated controls. Values are mean ± SEM (n = 3). PLGA, poly(lactic-co-glycolic acid); β-TCP, β-tricalcium phosphate; PCL, Polycaprolactone, Ki-67, proliferation marker; ALP, alkaline phosphatase; OPN, osteopontin; SPARC, osteonectin; VEGF, vascular endothelial growth factor; VDR, vitamin D nuclear receptor. Significantly different from control, **p < .01, ***p < .001.